SPRYHealthcareSmall-Cap

ARS Pharmaceuticals, Inc. Insider Trading Activity

Every SEC Form 4 insider transaction reported for ARS Pharmaceuticals, Inc. (SPRY), sourced directly from SEC EDGAR and updated as new filings are accepted.

Last updated:

Quick Answer

Are SPRY insiders buying or selling?

ARS Pharmaceuticals, Inc. insiders reported 16 open-market buys ($109.5M) and 88 sells ($121.4M) across 104 Form 4 filings — a net selling position of $11.9M.

Source: SEC EDGAR Form 4

Key Statistics (as of Jun 13, 2026)

Total Form 4 filings
104
SEC EDGAR
Insider filers
19
Insider buys (16)
$109.5M
Insider sells (88)
$121.4M

Insider sentiment

Net selling

Net insider flow of $11.9M in net selling.

Recent SPRY insider transactions

DateInsiderRoleTypeSharesPriceValue
Jun 13, 2026Eric KarasChief Commercial OfficerSale25.0K$10.00$250.0K
Jun 13, 2026Alexander A FitzpatrickChief Legal OfficerSale3.4K$10.00$33.5K
Nov 14, 2025Brian DorseyChief Operating OfficerSale21.8K$8.71$190.0K
Nov 14, 2025Justin ChakmaChief Business OfficerSale166.4K$8.87$1.5M
Aug 22, 2025Lowenthal Richard EPRESIDENT AND CEOSale50.0K$14.49$724.3K
Aug 22, 2025Kathleen D. ScottChief Financial OfficerSale12.5K$15.00$187.5K
Aug 21, 2025Tanimoto SarinaCHIEF MEDICAL OFFICERSale50.0K$14.08$703.8K
Jul 3, 2025Eric KarasChief Commercial OfficerSale15.0K$16.99$254.9K
Jul 1, 2025Flynn James E10% OwnerSale740.1K$18.46$13.7M
Jun 20, 2025Eric KarasChief Commercial OfficerSale15.0K$16.00$240.0K
May 22, 2025Alexander A FitzpatrickChief Legal OfficerSale103.0K$14.10$1.5M
May 22, 2025Brent L SaundersDirectorSale120.0K$14.25$1.7M
May 22, 2025Kathleen D. ScottChief Financial OfficerSale50.0K$14.10$705.2K
Apr 8, 2025Laura ShawverDirectorSale50.0K$12.30$615.1K
Mar 21, 2025Eric KarasChief Commercial OfficerSale10.0K$14.00$140.0K
Mar 7, 2025Laura ShawverDirectorSale50.0K$11.21$560.4K
Feb 4, 2025Laura ShawverDirectorSale50.0K$12.31$615.6K
Jan 7, 2025Laura ShawverDirectorSale50.0K$11.10$555.1K
Dec 19, 2024Tanimoto SarinaCHIEF MEDICAL OFFICERSale100.0K$11.67$1.2M
Dec 19, 2024Lowenthal Richard EPRESIDENT AND CEOSale100.0K$11.67$1.2M
Dec 14, 2024Justin ChakmaChief Business OfficerSale144.6K$12.23$1.8M
Dec 14, 2024Brian DorseyChief Operating OfficerSale40.0K$12.35$493.9K
Dec 12, 2024Justin ChakmaChief Business OfficerSale50.0K$13.15$657.6K
Dec 11, 2024Tanimoto SarinaCHIEF MEDICAL OFFICERSale100.0K$13.16$1.3M
Dec 11, 2024Lowenthal Richard EPRESIDENT AND CEOSale100.0K$13.16$1.3M

Showing the 25 most recent of 104 Form 4 filings for ARS Pharmaceuticals, Inc..

Most active SPRY insiders

  • Lowenthal Richard E23 filings
  • Tanimoto Sarina23 filings
  • Laura Shawver12 filings
  • Eric Karas7 filings
  • Justin Chakma6 filings

Ask anything about SPRY insider activity

Use Trabud's AI agent to query ARS Pharmaceuticals, Inc.'s Form 4 history in plain English — "Show me SPRY CEO purchases this year" or compare it against any other ticker.

Open the AI agent

SPRY insider trading FAQ

Are ARS Pharmaceuticals, Inc. insiders buying or selling?

Across 104 SEC Form 4 filings, ARS Pharmaceuticals, Inc. (SPRY) insiders reported 16 open-market purchases totaling $109.5M and 88 sales totaling $121.4M. That is a net selling position of $11.9M.

How many insiders trade SPRY stock?

19 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for ARS Pharmaceuticals, Inc.. The most recent filing was accepted on Jun 13, 2026.

Where does Trabud get SPRY insider trading data?

All SPRY insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.

Looking for another company? Browse all tracked companies.

Related Content